Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 13/20 | 0.66 |
| ▸ | CTSL | P07711 | 4/20 | 0.62 |
| ▸ | CTSS | P25774 | 3/20 | 0.62 |
| ▸ | CTSB | P07858 | 2/20 | 0.62 |
| ▸ | CAPN1 | P07384 | 3/20 | 0.60 |
| ▸ | CAPN2 | P17655 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8823912 | 0.95 | CTSK (0.65) | CTSKCTSLCTSSCTSBCAPN1 | |
| SCHEMBL8823951 | 0.95 | CAPN1 (0.63) | CTSKCTSLCTSSCTSBCAPN1 | |
| SCHEMBL8823894 | 0.93 | CTSK (0.69) | CTSKCTSLCTSSCTSBCAPN1 | |
| SCHEMBL8823920 | 0.92 | CTSK (0.61) | CTSKCTSLCTSSCTSBCAPN1 | |
| SCHEMBL8823893 | 0.92 | CTSK (0.59) | CTSKCTSLCTSSCTSBCAPN1 | |
| SCHEMBL8823903 | 0.92 | CTSK (0.59) | CTSKCTSLCTSSCTSBCAPN1 | |
| SCHEMBL7347217 | 0.91 | CTSK (0.64) | CTSKCTSLCTSSCTSBCAPN1 | |
| SCHEMBL27475014 | 0.91 | CTSK (0.64) | CTSKCTSLCTSSCTSBCAPN1 | |
| SCHEMBL8824084 | 0.89 | CTSK (0.61) | CTSKCTSLCTSSCTSBCAPN1 | |
| SCHEMBL14513408 | 0.89 | CTSK (0.64) | CTSKCTSLCTSSCTSBCAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1997049668-A1 | INHIBITIORS OF CYSTEINE PROTEASE | SMITHKLINE BEECHAM CORPORATION (US) | 1997-12-31 | — | — | WO | claimed |
| WO-1997049668-A1 | INHIBITIORS OF CYSTEINE PROTEASE | SMITHKLINE BEECHAM CORPORATION (US) | 1997-12-31 | — | — | WO | disclosed |